HER2 Support Group Forums - more on prognosis of her2+er- vs her2+ er+

This article's findings differ from others I have read

????peprhaps due to delay from specimen biopsy until formalin fixation???

Worthwhile reading the entire article (available to all@

http://breast-cancer-research.com/co...df/bcr2363.pdf

Summary does not do it justice:
Research article
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani , Sibylle Loibl , Berit M Muller , Marc Roller , Carsten Denkert , Martina Komor , Karsten Schluns , Jens-Uwe Blohmer , Jan Budczies , Bernd Gerber , Aurelia Noske , Andreas du Bois , Wilko Weichert , Christian Jackisch , Manfred Dietel , Klaus Richter , Manfred Kaufmann and Gunter von Minckwitz

Breast Cancer Research 2009, 11:R69doi:10.1186/bcr2363

Published: 16 September 2009
Abstract (provisional)

Introduction
Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable breast cancer to test for associations with pathological complete response (pCR) and disease-free survival (DFS). Particularly, we evaluated if interactions between hormone receptor (HR) and HER2 expression might lead to a different clinical behavior of HR+/HER2+ co-expressing and HR+/HER2- tumors and whether subgroups of triple negative tumors might be identified by the help of Ki67 labeling index, cytokeratin 5/6 (CK5/6), as well as cyclooxygenase-2 (COX-2), and Y-box binding protein 1 (YB-1) expression.

Methods
Expression analysis was performed using immunohistochemistry and silver-enhanced in situ hybridization on tissue microarrays (TMAs) of pretherapeutic core biopsies.

Results
pCR rates were significantly different between the biology-based tumor types (P=0.044) with HR+/HER2+ and HR-/HER- tumors having higher pCR rates than HR+/HER2- tumors. Ki67 labeling index, confirmed as significant predictor of pCR in the whole cohort (P=0.001), identified HR-/HER- (triple negative) carcinomas with a higher chance for a pCR (P=0.006). Biology-based tumor type (P=0.046 for HR+/HER2+ vs. HR+/HER2-), Ki67 labeling index (P=0.028), and treatment arm (P= 0.036) were independent predictors of pCR in a multivariate model. DFS was different in the biology-based tumor types (P<0.0001) with HR+/HER2- and HR+/HER2+ tumors having the best prognosis and HR-/HER2+ tumors showing the worst outcome. Biology-based tumor type was an independent prognostic factor for DFS in multivariate analysis (P<0.001).

Conclusions
Our data demonstrate that a biology-based breast cancer classification using estrogen receptor (ER), progesterone receptor (PgR), and HER2 bears independent predictive and prognostic potential. The HR+/HER2+ co-expressing carcinomas emerged as a group of tumors with a good response rate to neoadjuvant chemotherapy and a favorable prognosis. HR+/HER2- tumors had a good prognosis irrespective of a pCR, whereas patients with HR-/HER- and HR-/HER+ tumors, especially if they had not achieved a pCR, had an unfavorable prognosis and are in need of additional treatment options. Trial registration ClinicalTrials.gov identifier: NCT00793377